



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER					TWELVE MONTHS				
	2009	2008	% Change			2009	2008	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
CONSUMER SEGMENT ⁽²⁾										
SKIN CARE										
US	378	343	10.2%	10.2%	-	1,582	1,462	8.2%	8.2%	-
Intl	572	501	14.2%	6.7%	7.5%	1,885	1,919	-1.8%	3.9%	-5.7%
WW	950	844	12.6%	8.1%	4.5%	3,467	3,381	2.5%	5.7%	-3.2%
BABY CARE										
US	106	109	-2.8%	-2.8%	-	414	449	-7.8%	-7.8%	-
Intl	468	414	13.0%	5.0%	8.0%	1,701	1,765	-3.6%	1.7%	-5.3%
WW	574	523	9.8%	3.4%	6.4%	2,115	2,214	-4.5%	-0.2%	-4.3%
ORAL CARE										
US	167	192	-13.0%	-13.0%	-	716	780	-8.2%	-8.2%	-
Intl	241	204	18.1%	9.1%	9.0%	853	844	1.1%	8.6%	-7.5%
WW	408	396	3.0%	-1.7%	4.7%	1,569	1,624	-3.4%	0.5%	-3.9%
OTC/NUTRITIONALS										
US	807	762	5.9%	5.9%	-	2,944	3,061	-3.8%	-3.8%	-
Intl	767	694	10.5%	2.2%	8.3%	2,686	2,833	-5.2%	1.9%	-7.1%
WW	1,574	1,456	8.1%	4.2%	3.9%	5,630	5,894	-4.5%	-1.1%	-3.4%
WOMEN'S HEALTH										
US	135	148	-8.8%	-8.8%	-	578	618	-6.5%	-6.5%	-
Intl	354	288	22.9%	12.4%	10.5%	1,317	1,293	1.9%	8.4%	-6.5%
WW	489	436	12.2%	5.2%	7.0%	1,895	1,911	-0.8%	3.6%	-4.4%
WOUND CARE / OTHER										
US	119	101	17.8%	17.8%	-	603	567	6.3%	6.3%	-
Intl	135	99	36.4%	20.2%	16.2%	524	463	13.2%	19.9%	-6.7%
WW	254	200	27.0%	20.0%	7.0%	1,127	1,030	9.4%	12.2%	-2.8%
TOTAL CONSUMER										
US	1,712	1,655	3.4%	3.4%	-	6,837	6,937	-1.4%	-1.4%	-
Intl	2,537	2,200	15.3%	6.5%	8.8%	8,966	9,117	-1.7%	4.7%	-6.4%
WW	4,249	3,855	10.2%	5.2%	5.0%	15,803	16,054	-1.6%	2.0%	-3.6%

* See footnotes on page 3

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER					TWELVE MONTHS				
	2009	2008	% Change			2009	2008	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
PHARMACEUTICAL SEGMENT ⁽²⁾										
<u>ACIPHEX/PARIET</u>										
US	158	140	12.9%	12.9%	-	555	539	3.0%	3.0%	-
Intl	154	134	14.9%	2.7%	12.2%	541	619	-12.6%	-6.7%	-5.9%
WW	312	274	13.9%	8.0%	5.9%	1,096	1,158	-5.4%	-2.3%	-3.1%
<u>CONCERTA</u>										
US	279	208	34.1%	34.1%	-	986	830	18.8%	18.8%	-
Intl	102	72	41.7%	31.2%	10.5%	340	417	-18.5%	-11.9%	-6.6%
WW	381	280	36.1%	33.4%	2.7%	1,326	1,247	6.3%	8.5%	-2.2%
<u>DURAGESIC/FENTANYL TRANSDERMAL</u>										
US	53	72	-26.4%	-26.4%	-	216	271	-20.3%	-20.3%	-
Intl	180	200	-10.0%	-19.4%	9.4%	672	765	-12.2%	-8.3%	-3.9%
WW	233	272	-14.3%	-21.2%	6.9%	888	1,036	-14.3%	-11.4%	-2.9%
<u>LEVAQUIN/FLOXIN</u>										
US	433	393	10.2%	10.2%	-	1,478	1,510	-2.1%	-2.1%	-
Intl	19	18	5.6%	1.7%	3.9%	72	81	-11.1%	1.6%	-12.7%
WW	452	411	10.0%	9.8%	0.2%	1,550	1,591	-2.6%	-2.0%	-0.6%
<u>PROCRIPT/EPREX</u>										
US	308	318	-3.1%	-3.1%	-	1,258	1,332	-5.6%	-5.6%	-
Intl	268	242	10.7%	-0.3%	11.0%	987	1,128	-12.5%	-7.1%	-5.4%
WW	576	560	2.9%	-1.9%	4.8%	2,245	2,460	-8.7%	-6.2%	-2.5%
<u>RAZADYNE/REMINYL</u>										
US	6	11	-45.5%	-45.5%	-	36	134	-73.1%	-73.1%	-
Intl	104	91	14.3%	2.0%	12.3%	379	407	-6.9%	-0.5%	-6.4%
WW	110	102	7.8%	-3.2%	11.0%	415	541	-23.3%	-18.5%	-4.8%
<u>REMICADE</u>										
US	758	672	12.8%	12.8%	-	3,088	2,810	9.9%	9.9%	-
US Exports ⁽⁴⁾	375	209	79.4%	79.4%	-	1,196	927	29.0%	29.0%	-
Intl	5	5	-	-0.3%	0.3%	20	11	81.8%	78.8%	3.0%
WW	1,138	886	28.4%	28.4%	-	4,304	3,748	14.8%	14.8%	-
<u>RISPERDAL/RISPERIDONE</u>										
US	24	91	-73.6%	-73.6%	-	247	1,287	-80.8%	-80.8%	-
Intl	169	194	-12.9%	-20.9%	8.0%	652	839	-22.3%	-21.2%	-1.1%
WW	193	285	-32.3%	-37.8%	5.5%	899	2,126	-57.7%	-57.3%	-0.4%
<u>RISPERDAL CONSTA</u>										
US	133	117	13.7%	13.7%	-	519	456	13.8%	13.8%	-
Intl	266	202	31.7%	20.6%	11.1%	906	853	6.2%	14.5%	-8.3%
WW	399	319	25.1%	18.1%	7.0%	1,425	1,309	8.9%	14.3%	-5.4%
<u>TOPAMAX</u>										
US	89	576	-84.5%	-84.5%	-	731	2,250	-67.5%	-67.5%	-
Intl	103	104	-1.0%	-11.7%	10.7%	420	481	-12.7%	-5.3%	-7.4%
WW	192	680	-71.8%	-73.4%	1.6%	1,151	2,731	-57.9%	-56.6%	-1.3%
<u>VELCADE</u>										
US	-	-	-	-	-	-	4	-100.0%	-100.0%	-
Intl	281	208	35.1%	26.5%	8.6%	933	783	19.2%	26.7%	-7.5%
WW	281	208	35.1%	26.5%	8.6%	933	787	18.6%	26.0%	-7.4%
<u>OTHER</u>										
US	722	623	15.9%	15.9%	-	2,731	2,481	10.1%	10.1%	-
Intl	1,004	785	27.9%	19.1%	8.8%	3,557	3,352	6.1%	11.4%	-5.3%
WW	1,726	1,408	22.6%	17.7%	4.9%	6,288	5,833	7.8%	10.8%	-3.0%
<u>TOTAL PHARMACEUTICAL</u>										
US	3,338	3,430	-2.7%	-2.7%	-	13,041	14,831	-12.1%	-12.1%	-
Intl	2,655	2,255	17.7%	8.0%	9.7%	9,479	9,736	-2.6%	3.0%	-5.6%
WW	5,993	5,685	5.4%	1.6%	3.8%	22,520	24,567	-8.3%	-6.1%	-2.2%
MAJOR NEW PHARM PRODUCTS ⁽⁵⁾										
<u>PREZISTA</u>										
US	88	50	76.0%	76.0%	-	303	159	90.6%	90.6%	-
Intl	91	43	111.6%	98.7%	12.9%	289	175	65.1%	77.0%	-11.9%
WW	179	93	92.5%	86.5%	6.0%	592	334	77.2%	83.4%	-6.2%
<u>INVEGA</u>										
US	72	70	2.9%	2.9%	-	266	262	1.5%	1.5%	-
Intl	34	25	36.0%	23.8%	12.2%	127	64	98.4%	111.7%	-13.3%
WW	106	95	11.6%	8.4%	3.2%	393	326	20.6%	23.2%	-2.6%

* See footnotes on page 3

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER					TWELVE MONTHS				
	2009	2008	% Change			2009	2008	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
MEDICAL DEVICES AND DIAG ^{(2) (3)}										
<u>CORDIS ⁽⁶⁾</u>										
US	240	236	1.7%	1.7%	-	971	1,165	-16.7%	-16.7%	-
Intl	457	448	2.0%	-5.8%	7.8%	1,708	1,823	-6.3%	-4.4%	-1.9%
WW	697	684	1.9%	-3.2%	5.1%	2,679	2,988	-10.3%	-9.1%	-1.2%
<u>DEPUY</u>										
US	828	744	11.3%	11.3%	-	3,096	2,873	7.8%	7.8%	-
Intl	645	546	18.1%	8.3%	9.8%	2,276	2,263	0.6%	7.2%	-6.6%
WW	1,473	1,290	14.2%	10.1%	4.1%	5,372	5,136	4.6%	7.5%	-2.9%
<u>DIABETES CARE</u>										
US	313	275	13.8%	13.8%	-	1,221	1,265	-3.5%	-3.5%	-
Intl	342	304	12.5%	2.9%	9.6%	1,219	1,270	-4.0%	0.8%	-4.8%
WW	655	579	13.1%	8.0%	5.1%	2,440	2,535	-3.7%	-1.3%	-2.4%
<u>ETHICON</u>										
US	458	363	26.2%	26.2%	-	1,754	1,450	21.0%	21.0%	-
Intl	651	555	17.3%	7.5%	9.8%	2,368	2,390	-0.9%	4.5%	-5.4%
WW	1,109	918	20.8%	14.8%	6.0%	4,122	3,840	7.3%	10.7%	-3.4%
<u>ETHICON ENDO-SURGERY</u>										
US	532	515	3.3%	3.3%	-	1,974	1,901	3.8%	3.8%	-
Intl	724	602	20.3%	10.5%	9.8%	2,518	2,385	5.6%	10.6%	-5.0%
WW	1,256	1,117	12.4%	7.0%	5.4%	4,492	4,286	4.8%	7.6%	-2.8%
<u>ORTHO-CLINICAL DIAGNOSTICS</u>										
US	258	248	4.0%	4.0%	-	1,104	997	10.7%	10.7%	-
Intl	243	204	19.1%	10.6%	8.5%	859	844	1.8%	6.3%	-4.5%
WW	501	452	10.8%	6.9%	3.9%	1,963	1,841	6.6%	8.6%	-2.0%
<u>VISION CARE</u>										
US	188	201	-6.5%	-6.5%	-	891	890	0.1%	0.1%	-
Intl	430	401	7.2%	-0.7%	7.9%	1,615	1,610	0.3%	-	0.3%
WW	618	602	2.7%	-2.6%	5.3%	2,506	2,500	0.2%	0.1%	0.1%
<u>TOTAL MEDICAL DEVICES AND DIAG</u>										
US	2,817	2,582	9.1%	9.1%	-	11,011	10,541	4.5%	4.5%	-
Intl	3,492	3,060	14.1%	4.9%	9.2%	12,563	12,585	-0.2%	4.0%	-4.2%
WW	6,309	5,642	11.8%	6.8%	5.0%	23,574	23,126	1.9%	4.2%	-2.3%

⁽¹⁾ Operational growth excludes the effect of currency

⁽²⁾ Select areas (unaudited)

⁽³⁾ Prior year amounts have been reclassified to conform with current presentation

⁽⁴⁾ Reported in U.S. sales

⁽⁵⁾ Included in Other

⁽⁶⁾ Includes sales of Drug-Eluting Stents for Q4 2009 of \$56, \$167 and \$223MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for Q4 2008 of \$70, \$202 and \$272MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for December YTD 2009 of \$245, \$674 and \$919MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for December YTD 2008 of \$503, \$852 and \$1,355MM Domestic, International and Worldwide respectively